MX2023002996A - Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria. - Google Patents

Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria.

Info

Publication number
MX2023002996A
MX2023002996A MX2023002996A MX2023002996A MX2023002996A MX 2023002996 A MX2023002996 A MX 2023002996A MX 2023002996 A MX2023002996 A MX 2023002996A MX 2023002996 A MX2023002996 A MX 2023002996A MX 2023002996 A MX2023002996 A MX 2023002996A
Authority
MX
Mexico
Prior art keywords
treatment
hereditary hemorrhagic
hemorrhagic telangiectasia
akt inhibitors
allosteric akt
Prior art date
Application number
MX2023002996A
Other languages
English (en)
Spanish (es)
Inventor
Damien Picard
Pierre Saint-Mezard
Original Assignee
Vaderis Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaderis Therapeutics Ag filed Critical Vaderis Therapeutics Ag
Publication of MX2023002996A publication Critical patent/MX2023002996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2023002996A 2020-09-30 2021-09-29 Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria. MX2023002996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (1)

Publication Number Publication Date
MX2023002996A true MX2023002996A (es) 2023-05-03

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002996A MX2023002996A (es) 2020-09-30 2021-09-29 Inhibidores alostéricos de akt para su uso en el tratamiento de la telangiectasia hemorrágica hereditaria.

Country Status (13)

Country Link
US (1) US12466839B2 (cg-RX-API-DMAC7.html)
EP (1) EP4221713A1 (cg-RX-API-DMAC7.html)
JP (1) JP7900827B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230080448A (cg-RX-API-DMAC7.html)
CN (1) CN116419924A (cg-RX-API-DMAC7.html)
AU (1) AU2021352108B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023004885A2 (cg-RX-API-DMAC7.html)
CA (1) CA3192433A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000926A1 (cg-RX-API-DMAC7.html)
GB (1) GB2600384A (cg-RX-API-DMAC7.html)
IL (1) IL301466A (cg-RX-API-DMAC7.html)
MX (1) MX2023002996A (cg-RX-API-DMAC7.html)
WO (1) WO2022069552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
JP2008524339A (ja) 2004-12-15 2008-07-10 メルク エンド カムパニー インコーポレーテッド Akt活性のインヒビター
WO2006135627A2 (en) 2005-06-10 2006-12-21 Merck & Co., Inc. Inhibitors of akt activity
CA2656507C (en) 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
EP2120951A4 (en) 2006-12-06 2012-02-15 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
US8207169B2 (en) 2008-06-03 2012-06-26 Msd K.K. Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
US8957064B2 (en) 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
MX336865B (es) 2011-04-07 2016-02-04 Bayer Pharma AG Imidazopiridazinas como inhibidores de quinasa akt.
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
EP3678666B1 (en) 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Also Published As

Publication number Publication date
AU2021352108A9 (en) 2024-05-23
EP4221713A1 (en) 2023-08-09
CN116419924A (zh) 2023-07-11
CL2023000926A1 (es) 2023-11-03
JP2023543993A (ja) 2023-10-19
US20240092801A1 (en) 2024-03-21
CA3192433A1 (en) 2022-04-07
JP7900827B2 (ja) 2026-08-05
BR112023004885A2 (pt) 2023-04-18
GB202015536D0 (en) 2020-11-11
US12466839B2 (en) 2025-11-11
AU2021352108B2 (en) 2026-04-02
AU2021352108A1 (en) 2023-05-11
WO2022069552A1 (en) 2022-04-07
KR20230080448A (ko) 2023-06-07
IL301466A (en) 2023-05-01
GB2600384A (en) 2022-05-04

Similar Documents

Publication Publication Date Title
CO2026004964A2 (es) Moduladores de kras
CO2022015638A2 (es) Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso
UY38696A (es) Moduladores de alfa-1 antitripsina
MX2024010399A (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
MX2021002804A (es) Terapias de combinacion.
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023012725A (es) Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos.
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
MX2024008551A (es) Terapias de combinacion.
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
PE20200335A1 (es) Compuestos que inhiben la proteina mcl-1
MX2022002976A (es) Inhibidores selectivos de jak1.
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
DOP2010000191A (es) Derivados bis-(sulfonilamino)
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
CL2023000926A1 (es) Inhibidores alostéricos de akt para su uso en el tratamiento de telangiectasia hemorrágica hereditaria
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
MX2025014135A (es) Compuestos inhibidores de cinasa dependiente de ciclina para el tratamiento de trastornos medicos
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
CL2007002381A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno susu sales, solvatos o isomeros y uso de la combinacion con al menos un compuesto seleccionado entre diclofenaco, un corticosteroide, un antibiotico, un analgesico, un inmunomodulador, entre otros, para el tratamiento o profilaxis de la dermatitis